Cancer carbohydrate-based agents

The pharmaceutical impact of carbohydrate-based therapeutics can also be seen in the agents now under evaluation in pre-clini-cal and clinical development. For example, synthetic carbohydrate chains, modeled on tumor cell antigens but modified to stimulate an immune response, are being used to develop novel cancer vaccines. 

Based on in vivo experimental results reported, vitamin C can also be viewed as an inhibitor for the key enzymes involved in carbohydrate metabolism or glycolysis, including lactate dehydrogenase, which is involved in cancer cell metabolism (Hoffman, 1999, p. 395). The inference is that vitamin C is an anticancer agent, as advanced by Pauling and Hoffer. 

---